5-Amino-1MQ vs SLU-PP-332: What the Research Shows
5-Amino-1MQ and SLU-PP-332 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider 5-Amino-1MQ if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider SLU-PP-332 if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
What they have in common
- Only animal or lab studies of 5-amino-1MQ were found (e.g. obese mice): combined with a low-fat diet it promoted marked loss of adiposity and weight[2]
- Only animal or lab studies of SLU-PP-332 were found (e.g. mouse): In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism.[6]
Spec comparison
Showing 5 of 11 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength are the same or both unknown.
| Field | 5-Amino-1MQ | SLU-PP-332 |
|---|---|---|
| Class | NNMT inhibitor (not a peptide) | ERR agonist (not a peptide) |
| Also called | 5-amino, 1MQ | slupp, SLU-PP |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | WADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Scientific reports 2022, PMID 35013352 | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 0 human (0 randomized or controlled) of 7 summarised |
| Typical study doses |
| Not reported in study abstractsPubMed search, 11 Oct 2026 |
| Vial sizes sold | 5 mg, 10 mg | 5 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
5-Amino-1MQ and SLU-PP-332 together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Two non-peptide small molecules aimed at different targets
SLU-PP-332 is described as a synthetic agonist of the ERR family of nuclear receptors. 5-amino-1MQ is an NNMT enzyme inhibitor, so the two act on different targets.[12]
In mice, SLU-PP-332 raised energy expenditure and fatty acid oxidation and mimicked exercise effects on whole-body metabolism.[6]
In mouse models of metabolic syndrome, the ERR agonist also reduced obesity and improved insulin sensitivity.[6]
SLU-PP-332 beyond body weight, in mice and cells
In a mouse model of pressure-overload heart failure, SLU-PP-332 and a related compound, SLU-PP-915, improved ejection fraction and survival.[13]
In aging mice, 8 weeks of a pan-ERR agonist reversed age-related albuminuria and podocyte loss in the kidney.[14]
The only human-derived work cited used myoblasts cultured from muscle biopsies of inactive women, treated with SLU-PP-332 in the dish. It is cell data, not a result in people.[15]
A recent review of the pan-ERR agonists says clinical trials are needed to confirm efficacy and safety in humans.[16]
Anti-doping note
A paper on SLU-PP-332 metabolites states that WADA prohibits the use of exercise mimetics and metabolic modulators in sports.[17]
Common questions
Is SLU-PP-332 stronger than 5-amino-1MQ?
There is no basis to rank them. Both have animal or cell data only, and the endpoints differ: exercise-like metabolism and heart function for SLU-PP-332, adiposity alongside a diet change for 5-amino-1MQ.[6]
Are SLU-PP-332 and 5-amino-1MQ peptides?
Neither is described as a peptide in the cited abstracts. The 5MQ cell work calls it a small molecule inhibitor of NNMT, and SLU-PP-332 is described as a synthetic ERR agonist.[3]
Has SLU-PP-332 been tested in humans?
Not in the abstracts reviewed. The only human-derived material was cultured muscle cells, and a recent review says clinical trials are still needed.[16]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
- 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
- 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 12Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 13Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
- 14Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 15Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 16[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 17Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
Found an error? Report a correction.